Increasingly, women are choosing first-trimester risk assessment for Down syndrome and other aneuploid conditions. Recent studies have suggested that adding ultrasound assessment of the nasal bone to nuchal translucency thickness and maternal serum analytes in the first trimester will improve performance. This report assesses the current literature and discusses practical issues that must be addressed before widespread implementation of nasal bone screening in the United States.
First-trimester ultrasound assessment of the nasal bone may improve the performance of Down syndrome screening.
From the 1Department of Obstetrics and Gynecology, Columbia University Medical Center, New York, New York; 2Department of Obstetrics and Gynecology, David Geffen School of Medicine at University of California, Los Angeles, and for the Center for Fetal Medicine and Women's Ultrasound, Los Angeles, California.
* For members of the Nuchal Translucency Oversight Committee, see the Appendix.
Corresponding author: Todd Rosen, MD, 622 West 168th Street PH 16-66, New York, NY 10032; e-mail: firstname.lastname@example.org.
Financial Disclosure Dr. D'Alton is a consultant for Living MicroSystems, Inc (Watertown, MA) and a member of the MFMF Board of the Society of Fetal Medicine. Dr. Platt is a consultant for GE Medical Systems (Milwaukee, WI), Phillips Medical Systems (Bothell, WA), Living MicroSystems, Inc (Watertown, MA), and Perkin Elmer (Waltham, MA). The other authors have no potential conflicts of interest to disclose.